Study #2022-1003
A single-arm study of Pembrolizumab with Gemcitabine and Cisplatin as perioperative therapy for potentially resectable intrahepatic cholangiocarcinoma
MD Anderson Study Status
Enrolling
Treatment Agent
Pembrolizumab, Gemcitabine, Cisplatin
Description
To find out if adding pembrolizumab to standard of care chemotherapy drugs (cisplatin and gemcitabine) will improve long-term response of intrahepatic cholangiocarcinoma after surgery, compared to treatment with surgery and standard chemotherapy alone.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Cholangiocarcinoma
Study phase:
Phase II
Physician name:
Hop Tran Cao
Department:
Surgical Oncology
For general questions about clinical trials:
1-844-866-3603
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.